Breakthrough Nanotherapy for Colorectal Cancer: Innovative Research Involving NANBIOSIS
Breakthrough nanotherapy targets MSS colorectal cancer, inducing pyroptosis and immune activation. NANBIOSIS Units 1 and Unit 18 played a key role.
Barcelona, march 2024. For this World Colorectal Cancer Day, researchers from Dr. Mangues’ group (CB06/01/1031), in which NANBIOSIS Unit 18 is integrated, have published just last month a groundbreaking study on a novel targeted nanotherapy for colorectal cancer. Conducted in collaboration with three CIBER research groups across two thematic areas (BBN and ER), this research highlights the potential of CXCR4-targeted nanotoxic therapy to combat microsatellite stable (MSS) colorectal cancer, a subtype known for its resistance to immune checkpoint inhibitors and its immunosuppressive tumor environment.
The study, recently published in the International Journal of Nanomedicine, demonstrates the efficacy of CXCR4-targeted cytotoxic nanoparticles in an immunocompetent mouse model of MSS colorectal cancer. This innovative nanomedicine approach selectively eliminates cancer stem cells (CSCs) expressing the CXCR4 receptor by inducing pyroptosis, a type of programmed cell death that triggers a strong immune response. Notably, the treatment leads to the recruitment and activation of eosinophils, key immune cells that contribute to tumor destruction.
The findings emphasize the potential of pyroptosis-inducing nanotherapies to reprogram the tumor microenvironment and enhance innate immune responses against colorectal cancer. The involvement of NANBIOSIS Unit 1 and Unit 18 was instrumental in developing and characterizing this cutting-edge cancer nanotherapy. This contribution involved, respectivelly, the production of a significant range of the proteins used in the study, as well as the entire histological and toxicity studies.
For more details on this colorectal cancer breakthrough, access the full publication here: Dove Press
DOI: 10.2147/IJN.S499192
What is NANBIOSIS?
The goal of NANBIOSIS is to provide comprehensive and integrated advanced solutions for companies and research institutions in biomedical applications. All of this is done through a single-entry point, involving the design and production of biomaterials, nanomaterials, and their nanoconjugates. This includes their characterization from physical-chemical, functional, toxicological, and biological perspectives (preclinical validation).
In order to access our Cutting-Edge Biomedical Solutions with priority access, enter our Competitive Call here.
NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them:

